Which has grown faster, CRDF or HUMA?

Over the past five years, CRDF grew revenue faster — CRDF at a 5.15% CAGR versus HUMA at 2.41%.

How have CRDF and HUMA total returns compared?

Over the past 5 years, CRDF delivered -30.36% and HUMA delivered -45.73% annualized total return. Past performance doesn't predict future results.

Cardiff Oncology, Inc. (CRDF) vs Humacyte, Inc. (HUMA)

A side-by-side comparison of Cardiff Oncology, Inc. and Humacyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

CRDF

Cardiff Oncology, Inc.

$82M

$1.07HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

HUMA

Humacyte, Inc.

$80M

$0.48HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — CRDF vs HUMA

growth of $100 · dividends reinvested · last 6y

CRDF -95.4% (-40.1%/yr)HUMA -94.8% (-39.0%/yr)HUMA compounded faster over this window

CRDF HUMA

CRDF vs HUMA: by the numbers

•CRDF is the larger company ($82M vs $80M market cap).
•Both run net losses; HUMA's is the smaller (-4560.82% vs -7884.06% net margin).
•CRDF grew revenue faster over the past five years (5.15% vs 2.41% CAGR).

Metrics side by side

Valuation

Metric	CRDF	HUMA
P/S ratio	162.34	37.86
P/B ratio	3.11	2.57

Profitability

Metric	CRDF	HUMA
Gross margin	100.00%	-736.46%
Operating margin	-8256.32%	-5271.69%
Net margin	-7884.06%	-4560.82%
ROE	-150.95%	-309.44%
ROIC	-159.30%	-90.27%

Growth (annualized)

Metric	CRDF	HUMA
Revenue CAGR (5Y)	5.15%	2.41%
Total return CAGR (5Y)	-30.36%	-45.73%

Frequently asked

Which has grown faster, CRDF or HUMA?: Over the past five years, CRDF grew revenue faster — CRDF at a 5.15% CAGR versus HUMA at 2.41%.
How have CRDF and HUMA total returns compared?: Over the past 5 years, CRDF delivered -30.36% and HUMA delivered -45.73% annualized total return. Past performance doesn't predict future results.

Go deeper

Full CRDF analysis Full HUMA analysis Interactive comparison tool

Dig into the metrics

Cardiff Oncology ROE Humacyte ROE Cardiff Oncology operating margin Humacyte operating margin Cardiff Oncology revenue growth Humacyte revenue growth Cardiff Oncology free cash flow Humacyte free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.